Progress on SARS-CoV-2 3CLpro Inhibitors: Inspiration from SARS-CoV 3CLpro Peptidomimetics and Small-Molecule Anti-Inflammatory Compounds

被引：31
|
作者：
Zhu, Jiajie [1 ]
Zhang, Haiyan [2 ]
Lin, Qinghong [1 ]
Lyu, Jingting [1 ]
Lu, Lu [1 ]
Chen, Hanxi [1 ]
Zhang, Xuning [1 ]
Zhang, Yanjun [3 ]
Chen, Keda [1 ]
机构：
[1] Zhejiang Shuren Univ, Shulan Int Med Coll, Hangzhou, Peoples R China
[2] Zhejiang Chinese Med Univ, Hangzhou, Peoples R China
[3] Zhejiang Prov Ctr Dis Control & Prevent, Hangzhou, Peoples R China
来源：
DRUG DESIGN DEVELOPMENT AND THERAPY | 2022年 / 16卷
关键词：
SARS-CoV; SARS-CoV-2; 3CLpro; peptidomimetics; anti-inflammatory agents; small-molecule inhibitors; protease; inhibitors; CORONAVIRUS 3C-LIKE PROTEASE; MAIN PROTEASE; CRYSTAL-STRUCTURE; DIMER INTERFACE; PROTEINASE; MECHANISM; DESIGN; DISSOCIATION; DIMERIZATION; FLAVONOIDS;
D O I：
10.2147/DDDT.S359009
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) currently poses a threat to human health. 3C-like proteinase (3CLpro) plays an important role in the viral life cycle. Hence, it is considered an attractive antiviral target protein. Whole-genome sequencing showed that the sequence homology between SARS-CoV-2 3CLpro and SARS-CoV 3CLpro is 96.08%, with high similarity in the substrate-binding region. Thus, assessing peptidomimetic inhibitors of SARS-CoV 3CLpro could accelerate the development of peptidomimetic inhibitors for SARS-CoV-2 3CLpro. Accordingly, we herein discuss progress on SARS-CoV-2 3CLpro peptidomimetic inhibitors. Inflammation plays a major role in the pathophysiological process of COVID-19. Small-molecule compounds targeting 3CLpro with both antiviral and anti-inflammatory effects are also briefly discussed in this paper.
引用
收藏
页码：1067 / 1082
页数：16
相关论文
共 50 条
  • [41] Exploration of SARS-CoV-2 3CLpro Inhibitors by Virtual Screening Methods, FRET Detection, and CPE Assay
    Zhao, Jun
    Ma, Qinhai
    Zhang, Baoyue
    Guo, Pengfei
    Wang, Zhe
    Liu, Yi
    Meng, Minsi
    Liu, Ailin
    Yang, Zifeng
    Du, Guanhua
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2021, 61 (12) : 5763 - 5773
  • [42] Autoprocessing mechanism of severe acute respiratory syndrome coronavirus3C-like protease (SARS-CoV 3CLpro) from its polyproteins
    Muramatsu, Tomonari
    Kim, Yong-Tae
    Nishii, Wataru
    Terada, Takaho
    Shirouzu, Mikako
    Yokoyama, Shigeyuki
    FEBS JOURNAL, 2013, 280 (09) : 2002 - 2013
  • [43] A head-to-head comparison of the inhibitory activities of 15 peptidomimetic SARS-CoV-2 3CLpro inhibitors
    Vankadara, Subramanyam
    Wong, Yun Xuan
    Liu, Boping
    See, Yi Yang
    Tan, Li Hong
    Tan, Qian Wen
    Wang, Gang
    Karuna, Ratna
    Guo, Xue
    Tan, Shu Ting
    Fong, Jia Yi
    Joy, Joma
    Chia, C. S. Brian
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2021, 48
  • [44] Discovery of Nirmatrelvir Resistance Mutations in SARS-CoV-2 3CLpro: A Computational-Experimental Approach
    Havranek, Brandon
    Demissie, Robel
    Lee, Hyun
    Lan, Shuiyun
    Zhang, Huanchun
    Sarafianos, Stefanos
    Ayitou, Anoklase Jean-Luc
    Islam, Shahidul M.
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2023, 63 (22) : 7180 - 7188
  • [45] The main protease 3CLpro of the SARS-CoV-2 virus: how to turn an enemy into a helper
    Belenkaya, Svetlana V.
    Merkuleva, Iuliia A.
    Yarovaya, Olga I.
    Chirkova, Varvara Yu.
    Sharlaeva, Elena A.
    Shanshin, Daniil V.
    Volosnikova, Ekaterina A.
    Vatsadze, Sergey Z.
    Khvostov, Mikhail V.
    Salakhutdinov, Nariman F.
    Shcherbakov, Dmitriy N.
    FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, 2023, 11
  • [46] The Repurposed Drugs Suramin and Quinacrine Cooperatively Inhibit SARS-CoV-2 3CLpro In Vitro
    Eberle, Raphael J.
    Olivier, Danilo S.
    Amaral, Marcos S.
    Gering, Ian
    Willbold, Dieter
    Arni, Raghuvir K.
    Coronado, Monika A.
    VIRUSES-BASEL, 2021, 13 (05):
  • [47] Synthesis, in silico and in vitro studies of novel quinazolinone derivatives as potential SARS-CoV-2 3CLpro inhibitors
    Alamri, Mubarak A.
    Afzal, Obaid
    Akhtar, Md Jawaid
    Karim, Shahid
    Husain, Mohammed
    Alossaimi, Manal A.
    Riadi, Yassine
    ARABIAN JOURNAL OF CHEMISTRY, 2024, 17 (01)
  • [48] Development of a Cell-Based Luciferase Complementation Assay for Identification of SARS-CoV-2 3CLpro Inhibitors
    Rawson, Jonathan M. O.
    Duchon, Alice
    Nikolaitchik, Olga A.
    Pathak, Vinay K.
    Hu, Wei-Shau
    VIRUSES-BASEL, 2021, 13 (02):
  • [49] Bayesian Inference Elucidates the Catalytic Competency of the SARS-CoV-2 Main Protease 3CLpro
    Wralstad, Evans C.
    Sayers, Jessica
    Raines, Ronald T.
    ANALYTICAL CHEMISTRY, 2023, 95 (40) : 14981 - 14989
  • [50] Advances in developing small molecule SARS 3CLpro inhibitors as potential remedy for corona virus infection
    Konwar, Manashjyoti
    Sarma, Diganta
    TETRAHEDRON, 2021, 77
12345